The decision to end the programme comes 18 months after Genmab's former partner for the acasunlimab, BioNTech, pulled out of ...
The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...
A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...
Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish ...
AbbVie and Gilead Sciences each used the holiday season to reward their pipelines with a new clinical-stage cancer drug. | ...
The drug is not considered a cure, but results from clinical trials point to major advancement for a devastating cancer ...
Stocktwits on MSN
Genmab stock slips after discontinuing further development of cancer drug developed with BioNTech
The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial ...
The "Biological Therapies for Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...
In a new ACT video interview, Shanthi Sivendran, MD, MSCR, MBA, senior vice president for cancer care support at the American ...
Diabetes drugs may be doing more than managing blood sugar, they could also shape cancer biology in unexpected ways.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback